Roche has signed an agreement with DalCor Pharmaceuticals (DalCor) to develop a companion diagnostic (CDx) test for acute coronary syndrome (ACS).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The CDx test will be used in a Phase III clinical trial to evaluate the clinical efficacy of dalcetrapib, a therapeutic from DalCor, and will target patients with a specific genotype who have recently experienced ACS.

In addition, the test will assist in determining if a patient is eligible to receive the therapeutic treatment.

"The CDx test will be used in a Phase III clinical trial to evaluate the clinical efficacy of dalcetrapib, a therapeutic from DalCor, and will target patients with a specific genotype who have recently experienced ACS."

Roche Molecular Diagnostics head Paul Brown said: "Our first companion diagnostic test in cardiovascular disease represents a significant innovation and leverages our expertise in developing FDA approved CDx tests.

"Working with DalCor is a good opportunity for us to enter this market and deliver on our mission of personalised healthcare."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

DalCor Pharmaceuticals CEO Robert McNeil said: "The possibility of reducing morbidity and mortality for patients who have experienced ACS by identifying genetic markers that can respond to therapy, is an exciting prospect and one that we are eager to be a part of.

"The DalCor and Roche collaboration for the genetic testing is the right combination for successful execution of the Phase III trial."

Dalcetrapib is an investigational medicine, and according to a published analysis by the Montreal Heart Institute, it has the potential to lower cardiovascular morbidity and mortality by up to 39% in patients with a specific genetic profile.

Caused due to the sudden blockage of the blood supply to the heart muscle, ACS affects patients worldwide, and accounts for more than one million hospital admissions annually in the US.